A number of investment brokers have recently updated their price targets on shares of Cidara Therapeutics, Inc. (CDTX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

11/17/2015 – Cidara Therapeutics, Inc. had its “buy” rating reiterated by analysts at Needham & Company.

11/17/2015 – Cidara Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 22 price target on the stock.

10/09/2015 – Cidara Therapeutics, Inc. had its “hold” rating reiterated by analysts at WBB Securities. They now have a USD 13 price target on the stock.

05/27/2015 – BTIG Research began new coverage on Cidara Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 30 price target on the stock.

05/11/2015 – Leerink Swann began new coverage on Cidara Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 24 price target on the stock.

05/11/2015 – Jefferies began new coverage on Cidara Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 25 price target on the stock.

The share price of Cidara Therapeutics, Inc. (CDTX) was down -2.55% during the last day of trading, with a day high of 13.98. 34827 shares were traded during the last session.

The stock’s 50 day moving average is 12.95 and its 200 day moving average is 13.34. The stock’s market capitalization is 178.07M. Cidara Therapeutics, Inc. has a 52-week low of 9.48 and a 52-week high of 18.07.

View other investors thoughts on Cidara Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.